#### Baptist Health South Florida

#### Scholarly Commons @ Baptist Health South Florida

#### **All Publications**

5-2021

## Pharmacists' role in the management of patients receiving dual or triple antithrombotic therapy

Laura Neubauer Baptist Hospital of Miami, LauraNeu@baptisthealth.net

Radhan Gopalani Baptist Hospital of Miami, radhang@baptisthealth.net

Kristen de Almeida Baptist Hospital of Miami, KristenDe@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Part of the Cardiology Commons, Chemicals and Drugs Commons, and the Pharmacy and Pharmaceutical Sciences Commons

#### Citation

Neubauer, Laura; Gopalani, Radhan; and de Almeida, Kristen, "Pharmacists' role in the management of patients receiving dual or triple antithrombotic therapy" (2021). *All Publications*. 3990. https://scholarlycommons.baptisthealth.net/se-all-publications/3990

This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.



### Pharmacists' Role in the Management of Patients Receiving Dual or Triple Antithrombotic Therapy

Laura Provost, PharmD, BCPS PGY2 Cardiology Pharmacy Resident | Baptist Hospital of Miami LauraNeu@baptisthealth.net



### Disclosures

The authors for this project have nothing to disclose regarding any financial or nonfinancial relationships with the products described, reviewed, or evaluated in this presentation



•

### **Abbreviations**

- ACC American College of Cardiology
- ACS Acute Coronary Syndrome
- ADR 
   Adverse Drug Reaction
- APT
   Antiplatelet
- ASA Aspirin
- BHM
   Baptist Hospital of Miami
  - Coronary Artery Disease
- COVID 
   Coronavirus Disease
- DAT
   Dual Antithrombotic Therapy
- DAPT
   Dual Antiplatelet Therapy
- DOAC
   Direct Oral Anticoagulant
- DVT
   Deep Vein Thrombosis

- MVR Mitral Valve Repair
- NVAF Nonvalvular Atrial Fibrillation
- PAD Peripheral Artery Disease
  - PE Pulmonary Embolism
  - OAC Oral Anticoagulant

•

- TAT Triple Antithrombotic Therapy
- TAVR Transcatheter Aortic Valve Replacement

#### Laura Provost, Baptist Hospital of Miami

Summarize the most recent literature describing optimal antithrombotic therapy management in patients with an indication for both APT and OAC therapies

Review reported DAT / TAT-related ADRs at BHM during the year 2019 Discuss the clinical impact of pharmacist interventions in optimizing antithrombotic therapy in patients at BHM

3





### **Objectives**






Laura Provost, Baptist Hospital of Miami





### Background

- Major bleeding is associated with  $5x \uparrow risk$  of death after ACS
  - Addition of single APT to OAC  $\uparrow$  bleed risk up to 60%
  - Addition of dual APT to OAC further  $\uparrow$  this risk 2-3 fold
- <u>Goal</u>: Mitigate bleed risk while maintaining antithrombotic efficacy








## **Summary of Literature**

- Management of combination antithrombotic therapy is driven by:
  - Patient parameters, medication factors, guideline recommendations, indication, etc.
- Evolution of Triple Antithrombotic Therapy (TAT)




Most recent recommendations state that TAT be used for shortest duration possible (most often limited to duration of hospitalization)





### Antithrombotic-related ADRs at BHM

- Antithrombotics were #1 medication class associated with ADRs in 2019 (~29%)
- 28% of these ADRs included DAT or TAT regimens (>1 APT + IV/PO AC)



62

40

6

12

16

6

4





### **Research Purpose**

To evaluate pharmacists' role in the optimization of antithrombotic therapy in patients with concomitant indications for APT and OAC agents





Laura Provost, Baptist Hospital of Miami



### **Study Design**







	)	-0-
F	Ŧ	H

Single center


Quality Improvement Prospective

January – March 31<sup>st</sup> 2021



## **Eligibility Criteria**

# Hospitalized adult patients at Baptist Hospital receiving both an APT agent and OAC








### **Data Collection**

Daily report of hospitalized patients with active order for ≥1 antithrombotic agent

Filtered to include only patients receiving DAT or TAT Recommendations made based on clinical guidelines, indications & patient characteristics



### **Study Outcomes**



 Appropriateness of AC and APT regimens based on specific indications

- Type of pharmacist intervention
- Intervention acceptance rate







### **Baseline Demographics**

n= 239 Mean age, years (SD) 74.3 <u>+</u> 12.1 136 (56.9) Gender – male, n (%) Regimen - n (%) **Dual Therapy** 228 (95.4) ٠ Triple Therapy 11 (4.6) • APT Indication – n (%) CAD 130 (54.4) ٠ COVID 28 (11.7) ٠ CVA 22 (9.2) ٠ ACS 19 (7.9) . S/p Valve surgery 16 (6.7) ٠ PAD 11 (4.6) ٠ Not documented 7 (2.9) ٠ 1º prev. / ↑ ASCVD risk 6 (2.5) • OAC Indication – n (%) Atrial Fibrillation 172 (71.9) • 41 (17.2) DVT/PE treatment ٠ DVT/PE secondary ppx 15 (6.3) ٠ Other\* 11 (4.6) ٠

Antithrombotic Agents	n= 239
Antiplatelet Agents <ul> <li>ASA</li> <li>Clopidogrel</li> <li>Ticagrelor</li> </ul>	196 49 5
*11 patients were receiving 2 APT agents (TAT)	
Oral Anticoagulants • Apixaban • Rivaroxaban • Warfarin • Dabigatran	184 36 12 7


\*Intracardiac thrombus, valve surgery, PAD, portal vein thrombosis, s/p hip/knee replacement





### **Primary Outcome**

### **Regimen Appropriateness**



Laura Provost, Baptist Hospital of Miami





	Interventions Recommended	Interventions Accepted
Discontinue Agent	19	18
• APT	16	15
OAC	3	3
Increase OAC Dose	14	11
Apixaban	11	9
Rivaroxaban	2	2
Dabigatran	1	0
Decrease OAC Dose	10	6
Apixaban	5	2
Rivaroxaban	5	4
Alternative Agent Recommended	4	4
Total	47	39 (83.0%)





	Interventions Recommended	Interventions Accepted
Discontinue Agent	19	18
• APT	16	15
• OAC	3	3
Increase OAC Dose	14	11
Apixaban	11	9
Rivaroxaban	2	2
Dabigatran	1	0
Decrease OAC Dose	10	6
Apixaban	5	2
Rivaroxaban	5	4
Alternative Agent Recommended	4	4
Total	47	39 (83.0%)





	Interventions Recommended	Interventions Accepted
Discontinue Agent	19	18
• APT	16	15
OAC	3	3
Increase OAC Dose	14	11
• Apixaban	11	9
Rivaroxaban	2	2
<ul> <li>Dabigatran</li> </ul>	1	0
Decrease OAC Dose	10	6
Apixaban	5	2
Rivaroxaban	5	4
Alternative Agent Recommended	4	4
Total	47	39 (83.0%)





	Interventions Recommended	Interventions Accepted
Discontinue Agent	19	18
• APT	16	15
• OAC	3	3
Increase OAC Dose	14	11
Apixaban	11	9
Rivaroxaban	2	2
Dabigatran	1	0
Decrease OAC Dose	10	6
<ul> <li>Apixaban</li> </ul>	5	2
Rivaroxaban	5	4
Alternative Agent Recommended	4	4
Total	47	39 (83.0%)






	Interventions Recommended	Interventions Accepted
Discontinue Agent	19	18
• APT	16	15
OAC	3	3
Increase OAC Dose	14	11
Apixaban	11	9
Rivaroxaban	2	2
Dabigatran	1	0
Decrease OAC Dose	10	6
Apixaban	5	2
Rivaroxaban	5	4
Alternative Agent Recommended	4	4
Total	47	39 (83.0%)





## **Dual Antithrombotic Regimens**







## **Triple Antithrombotic Therapy**

TAT 27% Appropriate (n=11) 50 0 Intervention Acceptance Rate 100%

	Interventions Rec'd / Accepted
Discontinue APT	7 / 7
Increase OAC	2/2
Decrease OAC	1 / 1
Alternative Agent Rec'd	1 / 1
Total*	11 / 11

73% Inappropriate

\*8 unique regimens with 11 interventions

Accepted


100





### **Impact of Pharmacist Intervention**

Regimen Appropriateness



Intervention Acceptance Rate







### Discussion

- Dual antithrombotic therapy (APT + OAC) accounted for 95% of all regimens reviewed
- Triple antithrombotic therapies had the greatest opportunity for optimization
  - 73% inappropriate pre-intervention, 100% of interventions accepted
- Type of pharmacist intervention
  - Most common: APT discontinuation
  - Most clinically significant: OAC discontinuation





### Limitations

Short study duration (10 weeks)

Warfarin pharmacy consult and pre-approved automatic dose adjustment protocol in place to facilitate OAC dose optimization

Patients assessed for therapy optimization only once

Unable to assess long-term impact of RPh intervention on adverse outcomes





### Conclusion

Pharmacist intervention resulted in optimization of dual / triple antithrombotic therapies by 15%, with greatest impact seen with triple antithrombotic therapy

- Next steps:
  - Implement an automated alert that requires providers to acknowledge the use of triple therapy as well as intended duration
  - Pharmacist re-education regarding indication-specific dosing of OACs and indicated duration of therapy



### **Acknowledgements**

- Radhan Gopalani, PharmD, BCPS, BCCP
- Kristen de Almeida, PharmD, BCCP
- Ian Del Conde-Pozzi, MD



### **Self Assessment Question**

When indicated, what is the most appropriate duration of triple antithrombotic therapy for most patients?

- A. Until hospital discharge
- B. Indefinitely
- C. 1 year
- D. Triple therapy is never appropriate



### References

- Angiolillo DJ, Goodman SG, Eikelboom JW, et al. Antithrombotic Therapy in Patients with Atrial Fibrillation With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. *Circulation.* 2018;138:527-536.
- Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. *J Am Coll Cardiol.* 2021;77(5):629-658.
- So CH, Eckman MH. Combined Aspirin and Anticoagulant Therapy in Patients with Atrial Fibrillation. *J Thromb Thrombolysis.* 2017;43(1):7-17.
- Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients with Atrial Fibrillation and Renal Dysfunction. *J Am Coll Cardiol.* 2017;69(23):2779-90.



### Pharmacists' Role in the Management of Patients Receiving Dual or Triple Antithrombotic Therapy

Laura Provost, PharmD, BCPS PGY2 Cardiology Pharmacy Resident | Baptist Hospital of Miami LauraNeu@baptisthealth.net